ONO exercises Fate CAR-T option in latest twist to partners' four-year deal

Paul Schloesser

Associate Editor

While some of the biggest players have jumped on CAR-T therapies and their potential in medicine, one of the newest developments in the space involves …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

ONO exercises Fate CAR-T option in latest twist to partners' four-year deal

Paul Schloesser

Associate Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Large pharma companies spell out reasons why tariffs will harm US investments

Merck, Daiichi Sankyo scrap FDA application for HER3 ADC after survival miss

Supreme Court to keep mulling state PBM dispute as US urges justices to decline case

DNA giant Illumina spawned an ecosystem of competitors and customers

Intellia reports case of liver toxicity in ATTR gene editing study

From weeks to days: how Aizon Intelligent Agents transform pharma validation

ONO ex­er­cis­es Fate CAR-T op­tion in lat­est twist to part­ner­s' four-year deal

Associate Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

ONO exercises Fate CAR-T option in latest twist to partners' four-year deal